3 results
8-K
EX-2.1
IMNM
Immunome, Inc.
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
425
EX-2.1
IMNM
Immunome, Inc.
29 Jun 23
Business combination disclosure
9:10am
8-K
EX-2.1
IMNM
Immunome, Inc.
29 Jun 23
Immunome and Morphimmune Announce Definitive Merger Agreement
9:08am
- Prev
- 1
- Next